Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 33 results found. Search for [ Hetero Labs ]

Results 1 to 21 of 33
BusinessToday.In
June 14, 2021
Gilead Life Sciences, the innovator of the repurposed drug, had licensed six manufacturers in India to produce the drug. Export of Remdesivir injections/API against advance authorisations will not require separate permission


PB Jayakumar
May 3, 2021
Demand fell to almost nil by January after the first wave of the pandemic in the country. Since there was no demand, most manufacturers stopped giving fresh orders for manufacturing


BusinessToday.In
April 28, 2021
The company, known as Merck in the US and Canada, has inked pacts with Cipla, Dr Reddy's Laboratories, Sun Pharma, Hetero Labs, and Emcure Pharmaceuticals


PB Jayakumar
March 31, 2021
The Board of Directors of GlaxoSmithKline Pharmaceuticals approved the sale of the manufacturing facility


PTI
December 27, 2020
The vaccine development process by Bharat Biotech, Biological E Ltd and Aurobindo Pharma are currently in various stages, while Dr Reddy's and Hetero have tie ups for manufacturing the vaccine


PB Jayakumar
November 27, 2020
The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries. The safety of vaccines based on human adenoviruses has been confirmed in more than 75 international publications and in more than 250 clinical trials.


BusinessToday.In
October 16, 2020
The WHO said that the Solidarity trial looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients


BusinessToday.In
September 21, 2020
Chemcon Speciality Chemicals IPO: The specialised chemical products manufacturer is offering 93.52 lakh shares of Rs 10 each


BusinessToday.In
September 16, 2020
Chemcon Speciality Chemicals IPO: Price band for the IPO has been fixed at Rs  338 to Rs 340 per share


PB Jayakumar
August 13, 2020
Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical


Reuters
August 13, 2020
Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients


Reuters
July 29, 2020
Drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19 and will be available at drug stores from Wednesday, says Hetero


Reuters
July 9, 2020
Coronavirus update: The first batch of 10,000 vials had been printed with a price of 4,000 rupees, 800 rupees below the cheapest option, launched by European competitor Mylan this week


BusinessToday.In
July 6, 2020
Mylan has been licensed by Gilead for marketing the drug in 127 low- and middle-income countries, including India. The company will manufacture remdesivir at its injectables facilities in India


Reuters
June 25, 2020
Even with no existing approved vaccines, CEPI is already getting manufacturing and supply chains lined up in a quest to ensure coronavirus vaccines are distributed equitably around the globe


Reuters
June 25, 2020
Cipla and Hetero are among a bevy of drugmakers which have licensing agreements with US-based Gilead Sciences Inc, the original manufacturer of remdesivir, to make and sell the drug in 127 low- and middle-income countries


Reuters
June 23, 2020
Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees


Reuters
June 23, 2020
Indian drugmakers Hetero Labs and Cipla Ltd on Sunday gained approval to begin selling their generic versions of remdesivir in the country


BusinessToday.In
June 22, 2020
COVID-19 vaccine latest news: Biotechnology and pharmaceutical firms comprising Moderna Inc, and AstraZeneca, have been accelerating the pace of their production, promising millions of supplies of their experimental vaccines before this year-end


BusinessToday.In
June 22, 2020
India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for \"restricted emergency use\" on hospitalised COVID-19 patients


PAGES 1 OF 2  12